GlassScriptPhysician profile
Emelie Ilarde
NPI 1639194137
$10,802.06
in general payments reported to CMS, 2019-2025
35 companies · $1,881 in 2025
The $1,881 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,334 · 2020: $1,062 · 2021: $2,771 · 2022: $1,211 · 2023: $1,413 · 2024: $1,131 · 2025: $1,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,424.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,354.03 | 2021 | |
| Novo Nordisk INC | $1,280.46 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,157.12 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,056.44 | 2019-2025 | |
| Glaxosmithkline, LLC. | $970.78 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $733.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $519.19 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $496.11 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $442.91 | 2019-2025 | Jardiance |
| Madrigal Pharmaceuticals | $364.08 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $346.97 | 2022-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $298.01 | 2023-2025 | Rexulti |
| Allergan, INC. | $295.12 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $271.18 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $253.17 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $138.17 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.80 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $108.22 | 2022-2023 | |
| Ultragenyx Pharmaceutical INC. | $76.96 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.09 | 2022 | |
| Merck Sharp & Dohme LLC | $62.49 | 2021-2023 | Gardasil 9, Vaxneuvance |
| E.R. Squibb & Sons, L.L.C. | $60.68 | 2021-2022 | |
| Organon LLC | $56.97 | 2025 | Nexplanon |
| Abbott Laboratories | $42.85 | 2023-2024 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $33.14 | 2022-2023 | Tirosint, Licart |
| Genentech USA, INC. | $23.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.76 | 2021-2022 | |
| Exeltis, USA INC. | $20.24 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.85 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $19.52 | 2019 | |
| Radius Health, INC. | $18.46 | 2019 | |
| Hologic Sales and Service, LLC | $15.64 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.61 | 2020 | |
| Ironwood Pharmaceuticals, INC | $13.75 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emelie Ilarde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.